Siren L.L.C. Makes New Investment in Metsera Inc. $MTSR

Key Points

• Siren L.L.C. has invested approximately $4.08 million in Metsera Inc. by purchasing 150,000 shares during the first quarter of the year.
• Multiple hedge funds have also made new investments in Metsera, with significant purchases from New York State Common Retirement Fund and MetLife Investment Management totaling over $1 million collectively.
• Wall Street analysts have a generally positive outlook on Metsera, with price targets for the stock ranging from $50.00 to $77.00 and an average rating of "Buy."

Siren L.L.C. purchased a new position in Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,000 shares of the company's stock, valued at approximately $4,083,000. Siren L.L.C. owned 0.14% of Metsera at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. New York State Common Retirement Fund bought a new position in shares of Metsera in the first quarter worth approximately $131,000. Corebridge Financial Inc. bought a new position in shares of Metsera during the first quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Metsera during the first quarter worth $248,000. MetLife Investment Management LLC bought a new position in shares of Metsera during the first quarter worth $254,000. Finally, Invesco Ltd. bought a new position in shares of Metsera during the first quarter worth $271,000.

Metsera Trading Down 0.6%

MTSR stock opened at $36.50 on Thursday. Metsera Inc. has a 52 week low of $12.30 and a 52 week high of $47.40. The company has a fifty day simple moving average of $35.21 and a two-hundred day simple moving average of $28.76.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 target price for the company. Guggenheim upped their target price on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Bank of America upped their target price on shares of Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, August 28th. Leerink Partners assumed coverage on shares of Metsera in a research report on Tuesday. They set an "outperform" rating and a $77.00 target price for the company. Finally, Wall Street Zen lowered shares of Metsera from a "hold" rating to a "sell" rating in a research report on Sunday. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, Metsera presently has an average rating of "Buy" and an average price target of $63.50.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Want to see what other hedge funds are holding MTSR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metsera Inc. (NASDAQ:MTSR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.